Table 2: Changes in acylcarnitine levels (umol/L) with therapy.

MonthsLipid therapy C16:0
( )
C18:0
( 0.02–0.10)
C18:1
( )
C18:1-OH
( # n/a)
C2:0
( 3–23)
C3:0
( )
C total
( 21–70)
C free
( 13–56)

1Nil1.60.842.6421n/a9566
7Fenofibrate 145 mg + Ezetimibe 10 mg0.30.460.14n/a0.7110591
17Fenofibrate 145 mg1.31.340.720.02130.718668
30Nil1.82.60.80.80200.8010476
33Fenofibrate 96 mg1.20.441.46n/a200.79145119

# : provisional reference interval (umol/L).
C16:0: palmitoylcarnitine; C18:0: stearoylcarnitine; C18:1: oleoylcarnitine; C2:0: acetylcarnitine; C3:0: propionylcarnitine; C18:1-OH: hydroxyoleylcarnitine; C total: total carnitine; C free: free carnitine.